search 2013 adfgs

Board Members

Al Altomari

Agile Therapeutics, President and Chief Executive Officer

Al Altomari is the President and Chief Executive Officer of Agile Therapeutics and a member of the Company’s Board of Directors. Prior to being named President and CEO, Mr. Altomari served as Agile’s Executive Chairman in which capacity he closed a $45 million venture round in May 2010. Mr. Altomari has more than 28 years of experience in the pharmaceutical industry, with more than 20 years focused on the development and marketing of specialty pharmaceutical products. Currently Mr. Altomari is leading Agile through the final stages of development and commercialization of contraceptive products using the Company’s proprietary transdermal technology.

Read more »

Marc Bonnefoi, DVM, Ph.D.

Sanofi, Head, North America R&D Hub and Global Head, Drug Disposition, Preclinical Safety and Animal Research

Marc Bonnefoi is Head of Sanofi’ s North America R&D Hub which includes the R&D activities of Genzyme, Merial, Pharma, and Sanofi-Pasteur in the region. He also heads the global Scientific Core Platform Drug Disposition, Preclinical Safety and Animal Research, which support all Sanofi therapeutic units and Divisions.

Read more »

John F. Crowley

Amicus Therapeutics, Inc., Chairman and Chief Executive Officer

John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc.  John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the co-founder, president and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives.) In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

Read more »

Pamela M. Demain, MBA, CLP

Merck & Co., Inc., Executive Director, Transactions, Business Development and Licensing 

Pamela Demain is Executive Director, Transactions, Business Development and Licensing, Merck & Co., Inc.  She has been at Merck for over 30 years. For the past 19 years, she has been responsible for negotiating transactions with companies, universities and institutions worldwide, including arrangements for compounds, research collaborations, patents, formulations and research platform technologies.

Read more »

George Golumbeski, Ph.D.

Celgene Corporation, Senior Vice President, Business Development Celgene Corporation

In a career spanning nearly 20 years, George has held senior positions in R&D and Business Development. In his most recent two positions, he has led business development functions at leading oncology companies. He has a strong record of closing significant in-licensing and M&A transactions.

Read more »

Christian Kopfli, Esq.

Chromocell Corporation, Chief Executive Officer

Christian co-founded Chromocell in 2002, serving initially as General Counsel before becoming Chief Executive Officer in 2005.

Read more »

Will Lewis

Insmed Incorporated, President and Chief Executive Officer

Will joined Insmed in September 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Will has more than 20 years of executive experience and a track record of success in the pharmaceutical and finance industries both in the US and internationally.

Read more »

John Maki

Vicus Therapeutics, President and Chief Executive Officer

John Maki previously served as Managing Director of Technology Directors, Inc., as Managing Director of Audax Group and as Principal, Bain Capital, as well as consultant, Bain & Company.

Read more »

Anthony Marucci, MBA

Celldex Therapeutics, Inc., Founder, President, Chief Executive Officer and Director

Mr. Marucci is a Founder of Celldex and served as its Vice President, Chief Financial Officer, Treasurer and Secretary since inception and prior to his appointments to Executive Vice President in March 2008, President and Chief Executive Officer in October 2008, and the Board of Directors in December 2008.

Read more »

David Pearson, Ph.D., MBA

ThromboGenics, Inc., President and Global Head of Corporate DevelopmentThrombogenics

David Pearson, Ph.D., MBA, is an accomplished biopharmaceutical industry executive with more than 25 years of senior management experience in technical, operational and general management roles.  His passion has been the creation of innovative solutions to business, competitive and team challenges, while bridging the R&D, commercial and international worlds.

Read more »

Stuart W. Peltz, Ph.D.

PTC Therapeutics, Inc., Chief Executive Officer

Stuart W. Peltz, Ph.D. is a co-founder of PTC and has served as Chief Executive Officer and a member of the board of directors since the company’s inception in 1998.

Read more »

Spiro Rombotis

Cyclacel Pharmaceuticals, Inc., President & Chief Executive Officer

Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has 30 years of experience with biopharmaceutical companies. He was previously Vice President, International Operations and Business Development; Managing Director, Europe; and Representative Director, Japanese joint venture, at The Liposome Company, subsequently acquired by Elan. He held various executive roles at Bristol-Myers Squibb Company, most recently as Vice President, Pharmaceuticals Central and Eastern Europe. He was Head of European Marketing and Sales, Head of Corporate Development and one of the first employees of Centocor, subsequently acquired by Johnson & Johnson, and worked in Business Development at Novartis AG.

Read more »

Alan L. Rubino

EmisphereEmisphere Technologies, Inc., Chief Executive Officer

Alan L. Rubino joined Emisphere in 2012 as President and Chief Executive Officer. Upon joining, he was also appointed as Class II Director of the Company. Mr. Rubino’s career spans over 30 years at every level of the biopharmaceutical industry.

Read more »

Scott White

Janssen Biotech, Inc., Janssen Pharmaceutical Companies of Johnson & Johnson,  President, Oncology 

Scott began his career with Johnson & Johnson 24 years ago in R&D developing high-throughput screening assays for Drug Discovery followed by several years in Clinical Research and Development. He has enjoyed a broad and diverse career holding various discovery, clinical development, sales, marketing, and managed markets positions across the Johnson & Johnson family of companies. Read more »